

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

ANNOUNCEMENT PRINCIPAL FINANCIAL DATA AND INDICATORS OF FOSUN PHARMA FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2009

Reference is made to the overseas regulatory announcement dated 28 October 2009 (the "**Announcement**") and issued by Fosun International Limited (the "**Company**") in relation to the extract of the 2009 third quarter report of Shanghai Fosun Pharmaceuticals (Group) Co., Ltd. ("**Fosun Pharma**"), a subsidiary of the Company and whose A shares are listed and traded on the Shanghai Stock Exchange (Stock Code: 600196).

The board of directors of the Company would like to draw the attention of its shareholders and the investment public to the following principal financial data and indicators of Fosun Pharma for the nine months ended 30 September 2009 as set out in the Announcement:

Principal Financial Data and Indicators of Fosun Pharma

Unit: RMB yuan

	As at the end of this reporting period	As at the end of last year	Increase/decrease as at the end of this reporting period as compared with the end of last year (%)
Total assets	10,976,722,110.72	7,538,918,031.88	45.60
Owners' equity (or shareholders' equity) ⁽¹⁾	6,089,106,252.53	4,008,859,534.34	51.89
Equity per share attributable to shareholders of the listed company	4.92	3.24	51.85

	From the beginning of 2009 up to the end of this reporting period (January to September)		Increase/decrease as compared with the same period last year (%)
Net cash flow from operating activities	114,687,553.85		20.35
Net cash flow per share from operating activities	0.09		12.50
	Reporting period (July to September)	From the beginning of 2009 up to the end of this reporting period (January to September)	Increase/decrease of this reporting period as compared with the same period last year (%)
Net profit attributable to shareholders of the listed company ⁽²⁾	1,874,146,138.11	2,217,181,504.90	1,561.56
Basic earnings per share ⁽³⁾	1.51	1.79	1,577.78
Basic earnings per share net of non-recurring gain or loss	—	0.31	—
Diluted earnings per share	1.51	1.79	1,577.78
Fully diluted return on equity (%) ⁽³⁾	30.78	36.41	increased by 27.91 percentage points
Fully diluted return on equity net of non-recurring gain or loss (%)	2.15	6.29	decreased by 0.35 percentage point

Notes:

(1), (2) & (3) During the reporting period, due to the listing of Sinopharm Group Co. Ltd. (“**Sinopharm Group**”), invested by a subsidiary of Fosun Pharma, on The Stock Exchange of Hong Kong Limited, the corresponding equity shared by Fosun Pharma through Sinopharm Industrial Investment Co., Ltd. increased and was accounted for in the profit or loss for the reporting period. Due to the listing of Sinopharm Group, the owners’ equity attributable to shareholders of the listed company of Fosun Pharma increased by RMB1,731,941,569.64, the net profit attributable to shareholders of the listed company increased by RMB1,731,941,569.64 and the earnings per share increased by RMB1.40.

(4) The full text of the 2009 third quarter report of Fosun Pharma will be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>).

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, the PRC, 28 October 2009

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.